Home | Business News | Browse by Publication | M | M2 Presswire

(ENZN) SqueezeTrigger Price is $8.164. There is $90,842,230.00 That Short Sellers Still Need To Cover.

Article Excerpt
M2 PRESSWIRE-31 August 2007-BUYINS.NET: (ENZN) SqueezeTrigger Price is $8.164. There is $90,842,230.00 That Short Sellers Still Need To Cover(C)1994-2007 M2 COMMUNICATIONS LTD

RDATE:31082007

BUYINS.NET / www.squeezetrigger.com is monitoring ENZON PHARM INC (NASDAQ:ENZN) in real time and just received an alert that is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 11119000 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $8.164. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .

From January 2005 to July 2007, an aggregate amount of 111216246 shares of ENZN have been shorted for a total dollar value of $889,729,968.00. The ENZN SqueezeTrigger price of $8.164 is the volume weighted average price that all shorts are short in shares of ENZN. There is still approximately $90,842,230.00 of potential short covering in shares of ENZN.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .

ENZON PHARM INC (NASDAQ:ENZN)

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products for patients with cancer and other life-threatening diseases. The Company develops its products through the application of its technologies, as well as through transactions and partnerships. Its lead commercial product, ABELCET (amphotericin B lipid complex injection), is a lipid complex formulation of amphotericin B used primarily in the hospital to treat immuno-compromised patients, such...